Patents Examined by Howard E. Schain
  • Patent number: 5656597
    Abstract: The invention relates to lyospheres comprising gonadotropin, the preparation thereof, as well as pharmaceutical preparations containing the same.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 12, 1997
    Assignee: Akzo Nobel N.V.
    Inventors: Arnold Titus Philip Skrabanja, Herman Vromans
  • Patent number: 5652332
    Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
    Type: Grant
    Filed: September 15, 1994
    Date of Patent: July 29, 1997
    Assignee: XOMA
    Inventor: Roger G. Little, II
  • Patent number: 5652219
    Abstract: The invention provides compounds of general formula (I). The compounds have hemoregulatory activities and can be used to stimulate haematopoiesis and for the prevention and treatment of viral, fungal and bacterial infectious diseases.
    Type: Grant
    Filed: April 12, 1996
    Date of Patent: July 29, 1997
    Assignee: SmithKline Beecham Corporation
    Inventor: Pradip Kumar Bhatnagar
  • Patent number: 5652213
    Abstract: Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I: ##STR1## wherein R', R", R.sup.x1, R.sup.x2, R.sup.y1 -R.sup.y4, R.sup.z1, R.sup.z2, a, b, c, d, e, R.sup.0, R.sup.1 and R.sup.2 are defined as in the specification.
    Type: Grant
    Filed: March 11, 1996
    Date of Patent: July 29, 1997
    Assignee: Eli Lilly and Company
    Inventors: James A. Jamison, Michael J. Rodriguez, Lisa M. H. LaGrandeur, William W. Turner, Mark J. Zweifel
  • Patent number: 5650486
    Abstract: The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: July 22, 1997
    Assignee: Eli Lilly and Company
    Inventor: Michael R. De Felippis
  • Patent number: 5650549
    Abstract: A method and apparatus for photothermal detoxification of toxic organic compounds are provided. The apparatus comprises a means for maintaining the gas stream from the targeted source at a temperature of greater than 200.degree. C., an optional air pollution control device, a radiation source which emits radiation at a wavelength of less than 320 nm and an outlet for releasing the nontoxic reaction products to the atmosphere.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 22, 1997
    Assignee: The University of Dayton
    Inventors: Harold Barrett Dellinger, John L. Graham
  • Patent number: 5648335
    Abstract: The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.
    Type: Grant
    Filed: June 4, 1996
    Date of Patent: July 15, 1997
    Assignees: Cephalon, Inc., Albert Einstein College of Medicine of Yeshiva Univ.
    Inventors: Michael E. Lewis, Stuart C. Apfel, John A. Kessler
  • Patent number: 5646118
    Abstract: A product containing a) glutamine, L-amino acid of glutamine, N-acetyl-L-glutamine and/or glutamine-containing peptide;b) fatty acid containing 2-12 carbon atoms; andc) IGF-1 is useful for treating patients for atrophy of the gut mucosa.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: July 8, 1997
    Assignee: Pharmacia & Upjohn AB
    Inventors: Reinhold Kihlberg, Svante Bengt Lindgren, Lars Goran Sandberg
  • Patent number: 5646252
    Abstract: The described invention relates to an essentially stroma-free hemoglobin composition evidencing properties suitable for use as a universally applicable blood plasma expander and to a method for the preparation thereof. Typical, of these properties are desirable oxygen affinity values, desirable vascular retention time and substantial absence of toxic side effects. The described composition comprises human hemoglobin cross-linked intramolecularly through the beta-chains and polymerized with glutaraldehyde. Intramolecular cross-linking is typically effected with 2-nor-2-formylpyridoxal 5-phosphate or a bis-pyridoxal polyphosphate.
    Type: Grant
    Filed: October 16, 1995
    Date of Patent: July 8, 1997
    Assignee: Staat der Nederlanden, De Minister van Defensie, voor deze: Het Hoofd van de Afdeling Militair Geneeskundig Beleid
    Inventors: Wilhelmus Antonius Berbers, Petrus Theodorus Maria Biessels, Willem Karel Bleeker, Joachim Cornelis Bakker
  • Patent number: 5646116
    Abstract: A composition for the treatment of osteoporosis and the method of treatment of osteoporosis therewith in mammals is disclosed. The method comprises administering Insulin-Like Growth Factor I (IGF-I) to a mammal in need thereof. Need is determined by bone mineral density levels, whether by single measurement (as compared to the population generally) or by a series of measurements evidencing a loss of bone mineral density, or due to a genetic or familial or other predisposition to bone mineral density loss.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: July 8, 1997
    Assignee: Ciba-Geigy AG
    Inventor: Robert Roland Burk
  • Patent number: 5646111
    Abstract: Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I: ##STR1## wherein: R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --;R" and R'" are independently methyl or hydrogen;R.sup.x1, R.sup.x2, R.sup.y1, R.sup.y2, R.sup.y3, and R.sup.y4 are independently hydroxy or hydrogen;R.sub.0 is a group of the formula ##STR2## R.sub.1 is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, phenyl, p-halo-phenyl, p-nitrophenyl, phenoxy, benzyl, p-halo-benzyl, or p-nitro-benzyl; andR.sub.2 is an acyl side chain as defined herein.
    Type: Grant
    Filed: March 7, 1996
    Date of Patent: July 8, 1997
    Assignee: Eli Lilly and Company
    Inventors: Peter S. Borromeo, James A. Jamison, Michael J. Rodriguez, William W. Turner, Venkatraghaven Vasudevan
  • Patent number: 5646244
    Abstract: A compound of the formula: ##STR1## wherein A is benzyl group which has suitable substituent (s), A.sup.a, B and D are each lower alkyl,C is hydrogen or lower alkyl,or a salt thereof.The compound or its salt of the present invention has excellent parasiticidal activities as parasiticides (anthelmintics) for animals and human bodies.
    Type: Grant
    Filed: March 6, 1996
    Date of Patent: July 8, 1997
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Hitoshi Nishiyama, Masaru Ohgaki, Ryo Yamanishi, Toshihiko Hara
  • Patent number: 5646117
    Abstract: A therapeutic agent for treating wounds having properties and actions different from those of growth factors and proteins inducing growth factors, which have strong therapeutic effect is disclosed. The therapeutic agent for treating wounds according to the present invention comprises monocyte chemotactic and activating factor or a variation thereof having a monocyte-attracting property or a derivative of said monocyte chemotactic and activating factor or said variation thereof.
    Type: Grant
    Filed: July 12, 1995
    Date of Patent: July 8, 1997
    Assignee: Toray Industries, Inc.
    Inventors: Kouji Matsushima, Masanobu Naruto
  • Patent number: 5646113
    Abstract: Methods for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome, but not Laron syndrome, are described. One such method comprises administering a dose of greater than 0.3 mg/kg/week of growth hormone, preferably growth hormone with a native human sequence, with or without an N-terminal methionine, to the patient. The patient is characterized as having a height of less than about -2 standard deviations below normal for age and sex, serum levels of high-affinity growth hormone binding protein and IGF-I that are at least 2 standard deviations below normal levels, and a serum level of growth hormone that is at least normal. In another such method, the same patient population is treated with an effective amount of IGF-I alone or in combination with an amount of growth hormone that is effective in combination with IGF-I.
    Type: Grant
    Filed: April 7, 1994
    Date of Patent: July 8, 1997
    Assignee: Genentech, Inc.
    Inventors: Kenneth Attie, Lena Mariana Susann Carlsson, Neil Gesundheit, Audrey Goddard
  • Patent number: 5641749
    Abstract: The present invention relates generally to methods for treating injury or degeneration of retinal ganglion cells by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates specifically to methods for treating optic nerve injury or degeneration associated with glaucoma.
    Type: Grant
    Filed: November 29, 1995
    Date of Patent: June 24, 1997
    Assignee: Amgen Inc.
    Inventors: Qiao Yan, Jean-Claude Louis
  • Patent number: 5641750
    Abstract: The present invention relates generally to methods for treating injury or degeneration of retinal neurons, and in particular photoreceptors, by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates specifically to methods for treating retinal conditions or diseases in which vision is lost such as retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathies, photic retinopathies, surgery-induced retinopathies, viral retinopathies, ischemic retinopathies, retinal detachment and traumatic retinopathy.
    Type: Grant
    Filed: November 29, 1995
    Date of Patent: June 24, 1997
    Assignee: Amgen Inc.
    Inventor: Jean-Claude Louis
  • Patent number: 5637566
    Abstract: The present invention relates to the treatment of an animal to improve carcass quality and/or food conversion efficiency. The invention includes administering to an animal exogenous synthetic growth hormone at a frequency less than daily. The exogenous synthetic growth hormone is not orally administered and is not in a sustained release form. Animals including entire male, female, or castrated male pigs, bovine animals or sheep can be treated in this manner.
    Type: Grant
    Filed: March 28, 1995
    Date of Patent: June 10, 1997
    Assignee: Southern Cross Biotech Pty. Ltd.
    Inventors: Ian J. Walker, Roger G. Campbell
  • Patent number: 5637202
    Abstract: Porous plastic electrophoresis sponges having pore sizes range from 10.sup.-9 to 10.sup.-3 meters. The sponges are made from polyethylene, polypropylene, polytetrafluoroethylene, polyvinylidine difluoride, polynitrile or polystyrene. The porous plastic sponges are commercially available and are supplied in a prefabricated form which eliminates the preparative and pouring steps required for conventional gel electrophoresis support media. The porous sponges are available in a range of pore sizes and densities for use in a variety of electrophoresis systems to separate a variety of different materials including proteins, peptides and DNA. The porous electrophoresis sponges are relatively inert and may be used with organic solvents.
    Type: Grant
    Filed: March 8, 1995
    Date of Patent: June 10, 1997
    Assignee: California Institute of Technology
    Inventors: Michael G. Harrington, Kelvin H. Lee
  • Patent number: 5635477
    Abstract: This invention relates to novel cyclic compounds containing carbocyclic ring systems useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, with or without other therapeutic agents, and to methods of using these compounds, with or without other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of other thromboembolic disorders. This invention also relates to methods of using the cyclic compounds of the invention in combination with anti-coagulants such as warfarin or heparin, or additional anti-platelet agents such as aspirin, piroxicam or ticlopidine, or thrombin inhibitors such as boropeptides, hirudin or argatroban, or thrombolytic agents such as tissue plasminogen activator, anistreplase, urokinase or streptokinase, or combinations thereof, for the treatment of thromboembolic disorders. A representative compound of the invention is cyclo(D-Val-(.sup..alpha.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 3, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: William F. Degrado, Sharon A. Jackson, Shaker A. Mousa, Anju Parthasarathy, Michael Sworin, Maria Rafalski
  • Patent number: 5635475
    Abstract: Described are new glycoprotein hormones capable of competing with natural hormones for the normal receptor binding sites but substantially incapable of effecting post receptor activities. The glycoprotein hormones of the present invention have had specific (rather than all) oligosaccharide chains removed so as to effectively diminish biologic activity while not significantly reducing plasma half-life, thus improving the molecules effectiveness as an antagonist compared with conventionally-produced molecules. The preferred glycoprotein hormones are ideally obtained by site-directed mutagenesis to selectively deglycosylate the protein. Also described are therapeutic treatments comprising the administration of the recombinant glycoprotein hormones of the present invention as hormone antagonists.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: June 3, 1997
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Scott C. Chappel, Edward G. Bernstine